Tag: Oncology
PharmaSignal — Oncology therapeutic area
FDA delays decision on Sanofi’s subcutaneous Sarclisa
Pharmaphorum
The FDA has extended its review of a new version of Sanofi’s multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.
Merck’s fast-ascending kidney cancer drug hits a setback
BioPharma Dive
Welireg s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts said.
Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer
BioSpace
A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.
MSD, Eisai report setback in first-line kidney cancer trial
Pharmaphorum
The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.
Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls
BioSpace
The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer.
Jazz and Lilly cancer drugs cleared for use by NHS
Pharmaphorum
Jazz’s biliary tract cancer drug Ziihera and Lilly’s Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.
Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy
Pharmaceutical Business Review
The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility.
Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy
Pharmaceutical Technology
Pfizer and Astellas have received FDA acceptance for priority review of their sBLA for perioperative Padcev combined with Keytruda for MIBC.
AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
BioPharma Dive
Featured at this year s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and several targeted medicines for lung tumors.
S16 Ep55: OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer
OncLive Podcast
In this podcast, experts Joyce O’Shaughnessy, MD; Virginia Kaklamani, MD, DSc; and Seth A.
Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia
Pharmaphorum
Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.
S16 Ep53: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting
OncLive Podcast
In this podcast, experts Barbara Burtness, MD; and Quynh-Thu Le, MD, FACR, FASTRO; discuss recent and ongoing trials and key updates in the management of locally advanced head and neck cancer.
Multiple myeloma drug Blenrep backed for wider NHS use
Pharmaphorum
The revitalisation of GSK’s Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.
Revolution doubles stock offering target to $2B following pancreatic cancer win
BioSpace
After Revolution Medicines’ drug candidate doubled survival in a Phase 3 pancreatic cancer study, the biotech is hoping to attract more investor money, with new plans for a $2 billion stock and debt o
Terremoto wins $108m in Series C to drive cancer and rare disease programmes
Pharmaceutical Technology
Terremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity.
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Pharmaceutical Business Review
This Phase Ib/II study will measure the tolerability, safety, and early clinical activity by combining Boehringer Ingelheim’s DLL3 / cluster of differentiation 3 (CD3) T-cell engager, obrixtamig, with
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Pharmaceutical Technology
Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.
Adcendo secures $75m in Series C funding for ADC development
Pharmaceutical Technology
Adcendo, a clinical-stage biotechnology company developing ADCs for cancer treatment, has raised $75m in a Series C funding round.
Adcendo secures $75m in Series C funding for ADC development
Pharmaceutical Business Review
The financing will support Adcendo’s ongoing advancement of its first-in-class and best-in-class ADC pipeline targeting cancers of high unmet medical need, including further clinical development of th
J&J sets the tone for Q1 earnings with strong oncology growth
Pharmaceutical Technology
Off the back of J J’s positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med Icotyde